FBIO

What the company does

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

• 2026-05-14share offering or dilution eventrecentOpen filing ↗
  “…a post-effective amendment to certain prior Form S-3 registration statements to continue the registration of certain previously…”
  +1 more passage from the same document

  • “…2025. At the Market Offering During the three months ended March 31, 2026, the Company did no t issue any shares under the Company’s…”
• 2026-05-14listing compliance noticerecentOpen filing ↗
  “…to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries ​ ● We operate in a heavily regulated…”
  +1 more passage from the same document

  • “…a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may…”
• 2026-05-14capital return (buybacks/dividends)recentOpen filing ↗
  “…in interest expense and financing fees in the condensed consolidated statement of operations. In September 2025, upon the…”
  +1 more passage from the same document

  • “…recorded as a liability and accreted to the repurchase price, with accretion recognized as interest expense. For the quarter ended…”
• 2026-05-14Department of Justice inquiryrecentOpen filing ↗
  “…official to influence the foreign official in his or her official capacity, induce the foreign official to do or omit to do an…”
• 2026-05-14merger or acquisition eventrecentOpen filing ↗
  “…payments received in excess of an aggregate of $ 25.0 million, inclusive of certain specified prior payments. ​ In connection with…”
• 2026-03-31share offering or dilution eventrecentOpen filing ↗
  “…common stock related to equity plans — ​ — 582,323 ​ 1 ​ ( 1 ) ​ — ​ — ​ — Issuance of common stock under ESPP — ​ — 69,482 ​ — ​ 99…”
  +1 more passage from the same document

  • “…​ — 2,028,345 ​ 2 ​ 3,406 ​ — ​ — ​ 3,408 Warrants issued in conjunction with exchange of partner company's convertible preferred…”
• 2026-03-31listing compliance noticerecentOpen filing ↗
  “…the SEC. ● In February 2025, Mustang announced it had concurrently exited the lease for its manufacturing facility in Worcester,…”
  +1 more passage from the same document

  • “…3000 Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index…”
• 2026-03-31capital return (buybacks/dividends)recentOpen filing ↗
  “…of Operations for the year ended December 31, 2025. ​ F-19 Table of Contents Agreements with InvaGen In November 2018, Avenue…”
  +1 more passage from the same document

  • “…Company recognizes changes in fair value within general and administrative expenses in the consolidated statement of operations. In…”

3 older entries not shown

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:15 on Oct 10, 2023) · 1:15 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.